上海招聘

Responsibilities:

1. You will be responsible for product related business planning, timeline/resource/budget management, risk management, program/portfolio reporting;
2. You will host cross-functional discussion, governance meetings and external meetings. Maintain confluent information exchange flow and transparent team communications.
3. You will work with other PMs to plan, execute, control, report and close-out product related work across all functions.
4. You will ensure program work is conducted in compliance with PM best practice; You will utilize PMBOK methodology and facilitate lessons learned to ensure optimal performance.
5. You will function as core team member in co-development programs, manage and align on cross-company activities and objectives.
6. You will contribute to the success of the portfolio and project management office and be encouraged to share and learn within PM community.

Qualifications:

1. Life sciences or medical background is required. Post graduate degree in life sciences highly preferred;
2. PMP or PgMP certification or MBA degree is preferred;
3. At least 8 years of pharmaceutical industry experience is required; over 3 years' experience in research project management, clinical operations, CMC project management and other functional line management is preferred;
4. Skills in MS office is a must; Skills in MS project is preferred; Skills in other portfolio/program management system or tools (Planisware et al) is also preferred;
5. The ability to work with cross-functional teams in a matrix environment is a must;
6. Demonstrated ability to resolve conflict and influence teams without formal authority is required.

天境生物科技(上海)有限公司
天境生物由臧敬五博士领衔的创新药资深研发团队创建，是一家聚焦在肿瘤免疫和自身免疫疾病精准医疗领域的新药研发生物医药科技公司。
公司的核心竞争力在于早期研发、靶点发现和验证、工艺开发&临床前评价、质量科学&质量管理、早期临床研究的能力（包括临床一期和临床二期）。团队在创新药物靶点生物学、创新抗体药物分子结构研发以及创新药物的转化医学及临床研究方面的优势为公司建立一条具有国际竞争力的项目管线创造了基础。公司目前创新药管线含12个在研创新抗体药物项目。领先的创新药项目将在2017年3月申报临床研究并在台湾, 韩国及中国启动临床研究, 其它项目均已进入细胞株或工艺开发阶段。
公司从成立以来已经建立了广泛深入的国际合作, 如与瑞士FERRING公司合作独家引进开发Olamkicept。公司自主研发的全球创新药项目将在2018年进入中国及美国临床研究申报环节并计划在两地启动一期临床研究。